Latest news with #GermanHealthcare
Medscape
16 hours ago
- Health
- Medscape
SGLT2 Inhibitors Linked to Lower Risk for AF in T2D
The use of SGLT2 inhibitors was associated with a reduced risk for atrial fibrillation (AF) in patients with type 2 diabetes (T2D). METHODOLOGY: SGLT2 inhibitors have been shown to provide therapeutic benefits to patients with heart failure and AF; however, data on their protective effect on AF in patients without heart failure are inconsistent. Researchers conducted a retrospective case-control study in Germany to assess the association between the use of various antihyperglycemic medications between 2005 and 2023 and the diagnosis of AF in patients with T2D during the same period. They used data from the Disease Analyzer database including 29,424 patients with T2D aged 40 years or older with an initial diagnosis of AF who were matched to an equal number of control patients without AF (mean age at the index date , 76 years; 46%-47% women; average diabetes duration prior to the index date for both cohorts, 6.8 years). Antihyperglycemic therapies included metformin, sulfonylurea, GLP-1 receptor agonists (RAs), DPP-4 inhibitors, SGLT2 inhibitors, and insulin. TAKEAWAY: Treatment with SGLT2 inhibitors was associated with a reduced risk for AF (odds ratio [OR], 0.82; P < .01 per year of therapy). < .01 per year of therapy). GLP-1 RAs were associated with a slightly reduced risk for AF (OR, 0.93; P < .01), with a stronger association among women (OR, 0.89), patients aged 71-80 years (OR, 0.88), and patients older than 80 years (OR, 0.81; P < .01 for all). < .01), with a stronger association among women (OR, 0.89), patients aged 71-80 years (OR, 0.88), and patients older than 80 years (OR, 0.81; < .01 for all). The use of sulfonylurea was linked to a slightly increased risk for AF (OR, 1.09; P < .01), with the strongest association among patients younger than 70 years (OR, 1.18; P < .01). < .01), with the strongest association among patients younger than 70 years (OR, 1.18; < .01). Patients with AF began SGLT2 inhibitor therapy on average 2.6 years before diagnosis, with the therapy lasting an average of 2.3 years. IN PRACTICE: 'SGLT2i [inhibitors] and GLP-1 RA may provide an important, heretofore unknown effect of antidiabetic therapy: The prevention of AF, a cardiac condition of massive prevalence and severe impact for those affected,' the authors wrote. SOURCE: This study was led by Mark Luedde, MD, and Jamschid Sedighi, MD, of the University Hospital of Giessen and Marburg, Giessen, Germany. It was published online on June 03, 2025, in Diabetes, Obesity and Metabolism . LIMITATIONS: This study lacked data on the frequency and duration of AF episodes. The absence of data on cardiovascular disease severity may have affected the balance between groups. Potential bias due to the indication of oral antidiabetic treatments cannot be ruled out. DISCLOSURES: This study did not report any specific funding. The authors reported having no relevant conflicts of interest.
Yahoo
10-05-2025
- Business
- Yahoo
RHÖN-KLINIKUM First Quarter 2025 Earnings: EPS: €0.11 (vs €0.16 in 1Q 2024)
Revenue: €479.9m (up 5.3% from 1Q 2024). Net income: €7.14m (down 34% from 1Q 2024). Profit margin: 1.5% (down from 2.4% in 1Q 2024). The decrease in margin was driven by higher expenses. EPS: €0.11 (down from €0.16 in 1Q 2024). We check all companies for important risks. See what we found for RHÖN-KLINIKUM in our free report. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is expected to decline by 9.1% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to grow by 4.0%. Performance of the German Healthcare industry. The company's shares are down 12% from a week ago. While earnings are important, another area to consider is the balance sheet. See our latest analysis on RHÖN-KLINIKUM's balance sheet health. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
